SK3592001A3 - Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas - Google Patents
Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas Download PDFInfo
- Publication number
- SK3592001A3 SK3592001A3 SK359-2001A SK3592001A SK3592001A3 SK 3592001 A3 SK3592001 A3 SK 3592001A3 SK 3592001 A SK3592001 A SK 3592001A SK 3592001 A3 SK3592001 A3 SK 3592001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- adhd
- treatment
- receptor agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10119198P | 1998-09-21 | 1998-09-21 | |
| US10386898P | 1998-10-12 | 1998-10-12 | |
| PCT/IB1999/001503 WO2000016777A1 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3592001A3 true SK3592001A3 (en) | 2001-12-03 |
Family
ID=26798000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK359-2001A SK3592001A3 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US6300329B1 (es) |
| EP (1) | EP1115402A1 (es) |
| JP (1) | JP2002526448A (es) |
| KR (3) | KR20040054752A (es) |
| CN (1) | CN1319013A (es) |
| AP (1) | AP1456A (es) |
| AR (1) | AR029739A1 (es) |
| AU (1) | AU760230B2 (es) |
| BG (1) | BG105445A (es) |
| BR (1) | BR9913975A (es) |
| CA (1) | CA2344670A1 (es) |
| CO (1) | CO5140075A1 (es) |
| CZ (1) | CZ20011006A3 (es) |
| DZ (1) | DZ2894A1 (es) |
| EA (2) | EA200100204A1 (es) |
| EE (1) | EE200100179A (es) |
| GE (1) | GEP20033081B (es) |
| GT (1) | GT199900154A (es) |
| HN (1) | HN1999000146A (es) |
| HR (1) | HRP20010209A2 (es) |
| HU (1) | HUP0103691A3 (es) |
| ID (1) | ID28028A (es) |
| IL (2) | IL164839A0 (es) |
| IS (1) | IS5852A (es) |
| MA (1) | MA26690A1 (es) |
| MY (1) | MY127939A (es) |
| NO (1) | NO20011409L (es) |
| NZ (1) | NZ509855A (es) |
| OA (1) | OA11653A (es) |
| PA (1) | PA8482001A1 (es) |
| PE (1) | PE20001084A1 (es) |
| PL (1) | PL346904A1 (es) |
| SK (1) | SK3592001A3 (es) |
| TN (1) | TNSN99177A1 (es) |
| TR (2) | TR200101357T2 (es) |
| TW (1) | TW518225B (es) |
| WO (1) | WO2000016777A1 (es) |
| YU (1) | YU21701A (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1999000146A (es) * | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
| ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AU2002315336A1 (en) * | 2001-06-18 | 2003-01-02 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5ht-1a agonists |
| US20030036555A1 (en) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma Kg | Pramipexole for the treatment of ADHD |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| EP1765075A4 (en) * | 2004-06-10 | 2010-11-10 | Mclean Hospital Corp | PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS |
| EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION |
| MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
| GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| TW200800306A (en) | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| WO2008083442A1 (en) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Method for formulating combination medications for adhd |
| CN101318020B (zh) * | 2007-06-06 | 2011-09-28 | 四川科瑞德制药有限公司 | 抗焦虑或/和抗抑郁的药物组合物及用途 |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| GB201112987D0 (en) | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
| CN104892589A (zh) | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008148A1 (en) * | 1989-01-23 | 1990-07-26 | Pfizer Inc. | Bis-aza-bicyclic anxiolytic agents |
| WO1992000075A1 (en) * | 1990-06-29 | 1992-01-09 | Pfizer Inc. | Pyridopyrazine derivatives for treating substance abuse and addiction |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| GB9408084D0 (en) * | 1994-04-23 | 1994-06-15 | Boots Co Plc | Medical treatment |
| PT765320E (pt) * | 1994-06-14 | 2002-02-28 | Pfizer | Derivados da benzimidazolona com actividade dopaminergica central |
| US5877183A (en) * | 1996-06-06 | 1999-03-02 | Ergo Research Corporation | Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists |
| HN1999000146A (es) * | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
-
1999
- 1999-08-27 HN HN1999000146A patent/HN1999000146A/es unknown
- 1999-09-03 YU YU21701A patent/YU21701A/sh unknown
- 1999-09-03 GE GEAP19995812A patent/GEP20033081B/en unknown
- 1999-09-03 TR TR2001/01357T patent/TR200101357T2/xx unknown
- 1999-09-03 OA OA1200100068A patent/OA11653A/en unknown
- 1999-09-03 BR BR9913975-8A patent/BR9913975A/pt not_active IP Right Cessation
- 1999-09-03 CN CN99811132A patent/CN1319013A/zh active Pending
- 1999-09-03 KR KR10-2004-7006381A patent/KR20040054752A/ko not_active Application Discontinuation
- 1999-09-03 HU HU0103691A patent/HUP0103691A3/hu unknown
- 1999-09-03 IL IL16483999A patent/IL164839A0/xx unknown
- 1999-09-03 AP APAP/P/2001/002102A patent/AP1456A/en active
- 1999-09-03 KR KR10-2001-7003552A patent/KR100468340B1/ko not_active IP Right Cessation
- 1999-09-03 CA CA002344670A patent/CA2344670A1/en not_active Abandoned
- 1999-09-03 EE EEP200100179A patent/EE200100179A/xx unknown
- 1999-09-03 EA EA200100204A patent/EA200100204A1/ru unknown
- 1999-09-03 SK SK359-2001A patent/SK3592001A3/sk unknown
- 1999-09-03 TR TR2004/02083T patent/TR200402083T2/xx unknown
- 1999-09-03 EP EP99939567A patent/EP1115402A1/en not_active Withdrawn
- 1999-09-03 IL IL14150799A patent/IL141507A0/xx unknown
- 1999-09-03 ID IDW20010637A patent/ID28028A/id unknown
- 1999-09-03 PL PL99346904A patent/PL346904A1/xx unknown
- 1999-09-03 WO PCT/IB1999/001503 patent/WO2000016777A1/en not_active Application Discontinuation
- 1999-09-03 AU AU53831/99A patent/AU760230B2/en not_active Ceased
- 1999-09-03 EA EA200301063A patent/EA200301063A1/ru unknown
- 1999-09-03 CZ CZ20011006A patent/CZ20011006A3/cs unknown
- 1999-09-03 JP JP2000573738A patent/JP2002526448A/ja active Pending
- 1999-09-03 NZ NZ509855A patent/NZ509855A/xx unknown
- 1999-09-03 KR KR10-2003-7014169A patent/KR20030088512A/ko not_active Application Discontinuation
- 1999-09-13 GT GT199900154A patent/GT199900154A/es unknown
- 1999-09-15 TW TW088115941A patent/TW518225B/zh not_active IP Right Cessation
- 1999-09-15 PA PA19998482001A patent/PA8482001A1/es unknown
- 1999-09-17 PE PE1999000948A patent/PE20001084A1/es not_active Application Discontinuation
- 1999-09-17 MY MYPI99004051A patent/MY127939A/en unknown
- 1999-09-17 AR ARP990104680A patent/AR029739A1/es unknown
- 1999-09-20 MA MA25774A patent/MA26690A1/fr unknown
- 1999-09-20 TN TNTNSN99177A patent/TNSN99177A1/fr unknown
- 1999-09-20 DZ DZ990194A patent/DZ2894A1/xx active
- 1999-09-21 US US09/400,659 patent/US6300329B1/en not_active Expired - Fee Related
- 1999-09-21 CO CO99059863A patent/CO5140075A1/es unknown
-
2001
- 2001-02-20 IS IS5852A patent/IS5852A/is unknown
- 2001-03-20 NO NO20011409A patent/NO20011409L/no not_active Application Discontinuation
- 2001-03-20 HR HR20010209A patent/HRP20010209A2/hr not_active Application Discontinuation
- 2001-04-13 BG BG105445A patent/BG105445A/xx unknown
- 2001-05-03 US US09/848,068 patent/US6608064B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK3592001A3 (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
| Baladi et al. | Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor | |
| Ragozzino et al. | Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections | |
| Nikolic et al. | Imidazoline antihypertensive drugs: selective i1‐imidazoline receptors activation | |
| US20020037926A1 (en) | Sodium channel blocker compositions and the use thereof | |
| US5744476A (en) | Dopamine D1 agonists for the treatment of dementia | |
| US20070088074A1 (en) | Article of manufacture comprising aromatic amino acids isomers, analogs, or derivatives thereof to treat neurological disorders involving dysfunction of glutamatergic synaptic transmission | |
| JP2002541215A5 (es) | ||
| US20040220184A1 (en) | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | |
| Kuczenski et al. | Regional norepinephrine response to amphetamine using dialysis: comparison with caudate dopamine | |
| Angel et al. | Involvement of alpha-2 adrenergic receptor subtypes in hyperglycemia. | |
| US20070184490A1 (en) | Neuronal nicotinic receptor ligands and their use | |
| HRP20010584A2 (en) | N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance | |
| Ozaki et al. | Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro | |
| Chan et al. | Characterization of a KATP Channel—Independent Pathway Involved in Potentiation of Insulin Secretion by Efaroxan | |
| JPH1180027A (ja) | 向知性薬 | |
| MXPA01002946A (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, trastorno de hiperactividad con deficit de atencion y microadenomas | |
| JP2007524620A (ja) | 二重機能性化合物及びその使用 | |
| Ubaldi et al. | Investigation of allyphenyline efficacy in the treatment of alcohol withdrawal symptoms | |
| McBride et al. | Spiroxatrine augments fluoxetine-induced reduction of ethanol intake by the P line of rats | |
| Smyth et al. | Effects of central and peripheral neuropeptide Y on sodium and water excretion in the rat | |
| Halperin et al. | Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study | |
| Grözinger et al. | Antihistamines and sleep |